NCT02166892 is a NA clinical trial of Specially designed plates in Obesity, sponsored by Dan Nemet, MD.

Who is sponsoring NCT02166892?

NCT02166892 is sponsored by Dan Nemet, MD.

What drugs are being tested in NCT02166892?

Interventions in NCT02166892: Specially designed plates.

Is NCT02166892 still recruiting?

NCT02166892 is currently completed. Last updated 22 March 2018.

Last reviewed 2018-03-22 · How we verify

NCT02166892

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Specially Designed Eating Plates Effects on Food Intake in Normal Weight and Overweight Children

Completed NA Last updated 22 March 2018

What this trial tests

NA trial testing Specially designed plates in Obesity in 22 participants. Completed in 1 December 2017.

Timeline

1 July 2014

Primary endpoint
1 December 2017

1 December 2017

Quick facts

Lead sponsor	Dan Nemet, MD
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	22
Start date	1 July 2014
Primary completion	1 December 2017
Estimated completion	1 December 2017
Sites	1 location across Israel

Drugs / interventions tested

Specially designed plates

Conditions studied

Obesity — all drugs for Obesity →

Sponsor

Dan Nemet, MD

Who can join

Adults 4 to 13, any sex, with Obesity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Previous studies demonstrated that children served themselves more food when using larger plates and bowels. The purpose of this study is to evaluate if self-served portions and caloric intake in normal weight and overweight children will be influenced by a specially designed eating plates compared to similar size normal plates.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Obesity

Currently open trials in the same condition.

NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02166892 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dan Nemet, MD
Last refreshed: 22 March 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02166892.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing